AUROBINDO

October 17, 2020

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir,

Sub: Acquisition of 100% ownership of Eugia Pharma Specialities

We would like to inform that the Company has entered into a share purchase agreement today to acquire 100% equity share capital of MViyeS Pharma Ventures Private Limited (MViyeS).

MViyeS is holding 32.18% shareholding in Eugia Pharma Specialities Limited, a joint venture company in which the Company is holding 67.82%.

By this acquisition, both Eugia Pharma Specialities Limited and MViyeS Pharma Ventures Private Limited will become 100% subsidiaries of the Company.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is enclosed as **'Annexure I'.**

We request you to take the same on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

BADDIGAM ADI REDDY

Digitally signed by BADDIGAM ADI REDDY
DN: c=IN, o=Personal, 2.5.4.20=1249e67e239a72d275591952aaf4f0782b7b891e8cac84dffa9adbec758f170d, postalCode=500072, st=TELANGANA, serialNumber=b1f6dfc33c7d7f200e2371074a7575404dbe901e216efda16404f3ac51b96fca, cn=BADDIGAM ADI REDDY
Date: 2020.10.17 16:21:41 +05'30'

AUROBINDO PHARMA LTD. * HYDERABAD, INDIA *

B. Adi Reddy
Company Secretary

Encl: Annexure - I

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190) PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038. T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

AUROBINDO

Annexure -I

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	**i) Name of the Target :** MViyeS Pharma Ventures Private Limited (MViyeS) Registered office: Plot No.2, ALEAP Industrial Estate Gajularamaram, Hyderabad - 500072. **ii) Details of the Target:** MViyeS was incorporated in the year 2017 and holding 32.18% equity shares in Eugia Pharma Specialities Limited. No turnover during the last three financial years.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	Acquisition will not fall within the related party transaction.
c) Industry to which the entity being acquired belongs;	Pharmaceutical industry.
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To acquire 100% ownership of Eugia Pharma Speciailities Limited, a company engaged in developing, manufacturing and marketing hormonal and oncology generic formulations.
e) Brief details of any governmental or regulatory approvals required for the acquisition;	No approval is required.
f) Indicative time period for completion of the acquisition;	By 15th November 2020.
g) Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
h) Cost of acquisition or the price at which the shares are acquired;	Rs.274.22 crores for acquisition of total of 15,02,49,382 equity shares of Rs.10/- each at a price of Rs.18.25 per share.
i) Percentage of shareholding / control acquired and / or number of shares acquired;	After acquisition of shares, the Company will be holding 100% equity share capital in MViyeS.

AUROBINDO PHARMA LTD. HYDERABAD, INDIA

AUROBINDO

	Further, through Curepro Parentarals Limited (Curepro), a wholly owned subsidiary of the Company, the Company is holding 67.82% of equity share capital of Eugia Pharma Specialities Limited (Eugia) and MViyeS is holding the balance 32.18% of equity share capital of Eugia. On acquisition of entire share capital of MViyeS, both Eugia and MViyeS will become wholly owned subsidiaries of the Company.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	MViyeS has been incorporated on March 30, 2017 to hold equity stake in Eugia Pharma Specialities Limited It has no commercial operations hence, no turnover during the last three financial years.

AUROBINDO PHARMA LTD. HYDERABAD, INDIA